MB, Levis & Associates’s AstraZeneca AZN Stock Holding History

MB, Levis & Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$141K	Buy	+745	New	+$140K	0.05%	71
2026 Q1	–	Sell	-745	Closed	-$137K	–	235
2025 Q4	$137K	Hold	745	–	–	0.06%	67
2025 Q3	$114K	Buy	745 +4	+0.5%	+$605	0.05%	75
2025 Q2	$103K	Hold	741	–	–	0.05%	86
2025 Q1	$109K	Buy	741 +11	+2%	+$1.59K	0.05%	82
2024 Q4	$95.7K	Hold	730	–	–	0.05%	88
2024 Q3	$114K	Buy	730 +4	+0.6%	+$646	0.06%	78
2024 Q2	$113K	Hold	726	–	–	0.06%	78
2024 Q1	$98.3K	Buy	726 +11	+2%	+$1.46K	0.05%	86
2023 Q4	$96.3K	Hold	715	–	–	0.06%	83
2023 Q3	$96.8K	Buy	715 +5	+0.7%	+$683	0.06%	81
2023 Q2	$102K	Hold	710	–	–	0.07%	81
2023 Q1	$98.6K	Buy	710 +10	+1%	+$1.34K	0.07%	80
2022 Q4	$94.9K	Buy	+700	New	+$87.8K	0.07%	76

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

MB, Levis & Associates's AZN Position: Q2 2026 in Review

MB, Levis & Associates opened a new position in AstraZeneca (AZN) in Q2 2026: 745 shares worth $141K. The stake represents 0.05% of the portfolio and ranks #71 among its holdings. This is a return to the name: MB, Levis & Associates previously reported a position in AZN as recently as Q4 2025.

MB, Levis & Associates first reported a position in AZN in Q4 2022 and has held it in 14 quarters since. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

MB, Levis & Associates held 745 shares of AstraZeneca worth $141K as of Q2 2026.
AstraZeneca was a new MB, Levis & Associates position in Q2 2026.
AstraZeneca made up 0.05% of MB, Levis & Associates's portfolio in Q2 2026, its #71 holding.
MB, Levis & Associates first reported a position in AstraZeneca in Q4 2022 and has held it in 14 quarters since.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on MB, Levis & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.